CVA6-KM-J33 Strain for HFMD Vaccine Evaluation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current research lacks a Coxsackievirus A6 (CVA6) strain with desirable neutralizing ability, genetic stability, and strong virulence, which is crucial for developing effective vaccines and animal models for Hand-Foot-Mouth Disease (HFMD).

Innovation Solution

The CVA6 strain CVA6-KM-J33 is isolated, characterized, and propagated using human diploid cells, demonstrating strong virulence, high pathogenicity, and desirable immunogenicity, making it suitable for vaccine development and animal model construction.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If EV71 and CVA6 vaccines are applied, then the proportion of patients caused by CVA6 gradually increases, but the proportion of severe cases among CVA6 infection patients also increases

Engineering Contradiction:

Improvevaccine effectiveness against EV71VSAvoidseverity of CVA6 infection cases

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the parameter of viral strain selection by identifying and selecting the CVA6-KM-J33 strain with specific characteristics (high virulence, strong immunogenicity, good genetic stability) to replace previously used strains that did not adequately represent severe CVA6 cases, thereby enabling more accurate vaccine evaluation

Inventive Principle:

Principle #35Parameter changes

2Reliability

If clinically isolated CVA6 strains are used for research, then the pathogenic mechanism can be studied, but mice are generally less susceptible to clinically isolated strains making animal model construction difficult

Engineering Contradiction:

Improverepresentativeness of clinical strainsVSAvoidsusceptibility of mice to infection

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent uses the CVA6-KM-J33 strain as an intermediary that bridges the gap between clinical isolates and mouse susceptibility requirements, possessing both clinical relevance and high infectivity in mouse models

Inventive Principle:

Principle #24Intermediary (Mediator)

3Measurement precision

If a CVA6 strain with strong virulence is selected for vaccine evaluation, then the accuracy of immunogenicity evaluation can be improved, but the strain must also maintain genetic stability

Engineering Contradiction:

Improveaccuracy of immunogenicity evaluationVSAvoidgenetic stability of virus strain

Core Design Contradiction:

Measurement precisionVSStability of the object's composition

Solution Approach 1:

The patent optimizes the selection criteria by changing from using arbitrary clinical isolates to specifically selecting the CVA6-KM-J33 strain that has been characterized to possess both high virulence parameters and genetic stability, enabling accurate yet reliable vaccine evaluation

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS12215358B1Coxsackievirus A6 strain CVA6-KM-J33 and use thereof

Publication Date: 2025.02.04 INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI

AI summary

Provided is a Coxsackievirus A6 (CVA6) strain CVA6-KM-J33 and use thereof, and belongs to the technical field of biomedicine. The present invention provides a CVA6 strain CVA6-KM-J33, which belongs to a CVA6 virus. In the present invention, the strain CVA6-KM-J33 is susceptible to KMB17 cells and can achieve a relatively high titer. The strain has strong virulence, high pathogenicity and lethality to suckling mice, and desirable immunogenicity, and is a highly effective virus strain for CVA6 vaccine development. This strain can be used for immunogenicity evaluation or protective evaluation of CVA6 vaccine to improve the accuracy and reproducibility of vaccine immunogenicity evaluation. This strain can also be used to prepare animal models of Coxsackievirus (CV) infection, and exhibits desirable application prospects.